Table 1.

Chronic Myeloid Leukemia (CML) Treatments with Ex-Vivo Evidences of Effectiveness either in Combination with tyrosine kinase inhibitor (TKIs) or Alone.

Scheme Number	Treatment 1	Treatment 2	Pathway	References
1	Ponatinib	Asciminib	BCR-ABL1 allosteric inhibitor	[7]
2	Imatinib Dasatinib Nilotinib	GSK343	EZH2 inhibitor	[8]
3	Imatinib	LBH589	HDAC inhibitor	[9]
4	Nilotinib	LBH589	HDAC inhibitor	[10]
5	Imatinib	LAQ824	HDAC inhibitor	[11]
6	Imatinib	Hydralazine and Magnesium Valporate	HDAC inhibitors	[12]
7	Imatinib	Tenovin-6	SIRT1 inhibitor	[13]
8	Nilotinib	TV39OH	SIRT1 inhibitor	[14]
9	Imatinib	miR30a inhibition	Genetic repressor/activator	[15]
10	Imatinib	miR-202 overexpression	Inhibition of hexokinase 2 (HK2) and glycolysis	[16]
11	Imatinib	miR-486	Genetic repressor/activator	[17]
12	Imatinib	Ovatodiolide	miR-155 upregulation/PI3K/mTOR inhibition	[18]
13	Imatinib	RI-BPI	BCL6 inhibitor	[19]
14	Imatinib	FX1	BCL6 inhibitor	[20]
15	Imatinib	A-1210477	MCL-1 inhibitor	[20]
16	Dasatinib	Sabutoclax	Pan-BCL2 inhibitor	[21]
17	Imatinib	ABT-737	BCL2 and Bcl-xL inhibitor	[22,23]
18	Nilotinib	Nutlin3a ABT-737	MDM2 inhibitor BCL2 and Bcl-xL inhibitor	[24]
19	Imatinib	DS-5272	MDM2 inhibitor	[25]
20	Imatinib	ABT-199 (Venetoclax)	BCL2 inhibitor	[26]
21	Nilotinib	ABT-199 (Venetoclax)	BCL2 inhibitor	[27]
22	Imatinib Nilotinib Dasatinib	Chloroquine Bafilomycin A1	Autophagy inhibitors	[9,28]
23	Imatinib	Chloroquine Bafilomycin A1	Autophagy inhibitors	[29]
24	Imatinib Nilotinib Dasatinib	Clarithromycin	Autophagy inhibitor	[30]
25	Imatinib	Spautin-1	Autophagy inhibitor	[31]
26	Ponatinib	Vismodegib (GDC-0449)	Smo antagonist Hedgehog pathway	[32]
27	Nilotinib	Lys05	Autophagy inhibitor	[33]
28	Nilotinib	PIK-III	VPS34 inhibitor Autophagy	[33]
29	Imatinib	PTC-209	BMI1 inhibitor	[34]
30	Nilotinib	WNT974	PORCN selective inhibitor Wnt pathway	[35]
31	Nilotinib	PRI-724	CBP inhibitor Wnt/β-catenin inhibition	[36]
32	Nilotinib	XL880 R428	AXL inhibitors	[37]
33	Imatinib	Plerifaxor (ADM3100)	CXCR4 antagonist	[34]
34	Imatinib Nilotinib	Plerifaxor (ADM3100)	CXCR4 antagonist	[38]
35	Nilotinib	Plerifaxor (ADM3100)	CXCR4 antagonist	[39]
36	Imatinib	BTK140	CXCR4 antagonist	[40]
37	Imatinib	Filgotinib Itacitinib	JAK1 specific inhibitors, JAK1/STAT3 pathway	[41]
38	Imatinib	Wogonin	STAT5 pathway inhibitor	[42]
39	Imatinib	Tigecycline	Mitochondrial ribosome protein translation and respiratory chain	[43]
40	Nilotinib	SR18292	PGC-1α inhibitor/SIRT1 pathway inhibition	[14]
41	Imatinib Dasatinib	Ivermectin	mTOR inhibitor	[44]
42	Imatinib	Anti-CD70	Wnt/β-catenin inhibition	[45]
43	Imatinib	Sonidegib (LDE225)	Smo antagonist Hedgehog pathway inhibition	[46]
44	Imatinib	Ly364947	TGF-βRI inhibitor TGFβ/Activin/NODAL pathway	[47]
45	Imatinib Dasatinib Ponatinib	EW-7197	TGF-β signaling inhibitor	[11]
46	Dasatinib	BMS-911543	JAK2 inhibitor	[48]
47	Dasatinib	Niclosamide	ERK/MNK1/eIF4E pathway inhibition	[49]
48	Imatinib	SB216763	GSK-3 specific inhibitor	[50]
49	Imatinib Nilotinib	PD146176	15-LO inhibition/ arachidonic acid -leukotriene pathway inhibition	[51]
50	none	EZH2 CRISPR/Cas9 invalidation	EZH2 inhibition	[52]
51	none	Pracinostat	HDAC inhibitor	[53]
52	none	PJ-68	Methyltransferase inhibitor (PRMT5) Wnt/β-catenin pathway inhibition	[54]
53	none	Dactolisib (BEZ235) Chloroquine	PI3K/mTOR inhibitor Autophagy inhibitor	[55]
54	none	Vismodegib (GDC-0449)	Smo antagonistHH pathway inhibition	[56]
55	none	Resveratrol	Autophagic cell death induction	[57]
56	none	IFN-α Ruxolitinib	MHC II increased expression JAK1/2 inhibitor	[58]
57	none	shATG7	Mitochondrial ROS and oxidative phosphorylation increase Autophagy inhibition	[59]
58	none	miR-326 overexpression	Downregulation of SmoHH pathway inhibition	[60]
59	none	PD184352 BMS-21462	MEK specific inhibitor Farnesyl transferase inhibitor	[61]
60	none	CGP57380	MNK1 inhibitor ERK/MNK1/eIF4E pathway inhibition	[62]
61	none	LY255283	BLT2 inhibitor/arachidonic acid -leukotriene pathway inhibition	[63]
62	none	RG7112/7388 CPI-203/0610	HMD2 inhibitors (p53 inhibition) BET inhibitors (c-Myc inhibition)	[64]